Epidemiologic evidence indicates that diabetes may increase risk of breast cancer (BC) and mortality in patients with cancer. The pathophysiological relationships between diabetes and cancer are not fully understood, and personalized treatments for diabetes-associated BC are urgently needed.
Results:
We observed that high glucose (HG), via activation of nuclear phosphatase PP2Cδ, suppresses p53 function, and consequently promotes BC cell proliferation, migration, and invasion. PP2Cδ expression is higher in tumor tissues from BC patients with hyperglycemia than those with normoglycemia. The mechanisms underlying HG stimulation of PP2Cδ involve classical/novel protein kinase-C (PKC) activation and GSK3β phosphorylation. Reactive oxygen species (ROS)/NF-κB pathway also mediates HG induction of PP2Cδ. Furthermore, we identified a 1,5-diheteroarylpenta-1,4-dien-3-one (Compound 23, or C23) as a novel potent PP2Cδ inhibitor with a striking cytotoxicity on MCF-7 cells through cell-based screening assay for growth inhibition and activity of a group of curcumin mimics. Beside directly inhibiting PP2Cδ activity, C23 blocks HG induction of PP2Cδ expression via heat shock protein 27 (HSP27) induction and subsequent ablation of ROS/NF-κB activation. C23 can thus significantly block HG-triggered inhibition of p53 activity, leading to the inhibition of cancer cell proliferation, migration, and invasion. In addition, hyperglycemia promotes BC development in diabetic nude mice, and C23 inhibits the xenografted BC tumor growth.
Conclusions and Innovation:
Our findings elucidate mechanisms that may have contributed to diabetes-associated BC progression, and provide the first evidence to support the possible alternative therapeutic approach to BC patients with diabetes. Antioxid. Redox Signal. 30, 1983–1998.
ArrigoAP, VirotS, ChaufourS, FirdausW, Kretz-RemyC, and Diaz-LatoudC. Hsp27 consolidates intracellular redox homeostasis by upholding glutathione in its reduced form and by decreasing iron intracellular levels. Antioxid Redox Signal, 7: 414–422, 2005.
3.
BecknerME, StrackeML, LiottaLA, and SchiffmannE. Glycolysis as primary energy source in tumor cell chemotaxis. J Natl Cancer Inst, 82: 1836–1840, 1990.
4.
BhateliaK, SinghA, TomarD, SinghK, SripadaL, ChagtooM, PrajapatiP, SinghR, GodboleMM, and SinghR. Antiviral signaling protein MITA acts as a tumor suppressor in breast cancer by regulating NF-kappaB induced cell death. Biochim Biophys Acta, 1842: 144–153, 2014.
5.
BilanDS, PaseL, JoosenL, GorokhovatskyAY, ErmakovaYG, GadellaTW, GrabherC, SchultzC, LukyanovS, and BelousovVV. HyPer-3: a genetically encoded H(2)O(2) probe with improved performance for ratiometric and fluorescence lifetime imaging. ACS Chem Biol, 8: 535–542, 2013.
6.
BjorgeT, LukanovaA, JonssonH, TretliS, UlmerH, ManjerJ, StocksT, SelmerR, NagelG, AlmquistM, ConcinH, HallmansG, HaggstromC, StattinP, and EngelandA. Metabolic syndrome and breast cancer in the me-can (metabolic syndrome and cancer) project. Cancer Epidemiol Biomark Prev, 19: 1737–1745, 2010.
7.
BoyleP, BoniolM, KoechlinA, RobertsonC, ValentiniF, CoppensK, FairleyLL, BoniolM, ZhengT, ZhangY, PasterkM, SmansM, CuradoMP, MullieP, GandiniS, BotaM, BolliGB, RosenstockJ, and AutierP. Diabetes and breast cancer risk: a meta-analysis. Br J Cancer, 107: 1608–1617, 2012.
8.
BulavinDV, DemidovON, SaitoS, KauraniemiP, PhillipsC, AmundsonSA, AmbrosinoC, SauterG, NebredaAR, AndersonCW, KallioniemiA, FornaceAJJr., and AppellaE. Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity. Nat Genet, 31: 210–215, 2002.
9.
ButlerAM, Scotti BuzhardtML, ErdoganE, LiS, InmanKS, FieldsAP, and MurrayNR. A small molecule inhibitor of atypical protein kinase C signaling inhibits pancreatic cancer cell transformed growth and invasion. Oncotarget, 6: 15297–15310, 2015.
10.
DangCV and SemenzaGL. Oncogenic alterations of metabolism. Trends Biochem Sci, 24: 68–72, 1999.
11.
DerrRL, YeX, IslasMU, DesideriS, SaudekCD, and GrossmanSA. Association between hyperglycemia and survival in patients with newly diagnosed glioblastoma. J Clin Oncol, 27: 1082–1086, 2009.
12.
DouarreC, MerguiX, SidibeA, GomezD, AlbertiP, MaillietP, TrentesauxC, and RiouJF. DNA damage signaling induced by the G-quadruplex ligand 12459 is modulated by PPM1D/WIP1 phosphatase. Nucleic Acids Res, 41: 3588–3599, 2013.
13.
FriesnerRA, BanksJL, MurphyRB, HalgrenTA, KlicicJJ, MainzDT, RepaskyMP, KnollEH, ShelleyM, PerryJK, ShawDE, FrancisP, and ShenkinPS. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem, 47: 1739–1749, 2004.
14.
GarmendiaML, PereiraA, AlvaradoME, and AtalahE. Relation between insulin resistance and breast cancer among Chilean women. Ann Epidemiol, 17: 403–409, 2007.
15.
GezgenG, RoachEC, KizilarslanogluMC, PetekkayaI, and AltundagK. Metabolic syndrome and breast cancer: an overview. J BUON, 17: 223–229, 2012.
16.
GrahamML, JanecekJL, KittredgeJA, HeringBJ, and SchuurmanHJ. The streptozotocin-induced diabetic nude mouse model: differences between animals from different sources. Comp Med, 61: 356–360, 2011.
17.
GranjaAG, NogalML, HurtadoC, SalasJ, SalasML, CarrascosaAL, and RevillaY. Modulation of p53 cellular function and cell death by African swine fever virus. J Virol, 78: 7165–7174, 2004.
18.
JeeSH, OhrrH, SullJW, YunJE, JiM, and SametJM. Fasting serum glucose level and cancer risk in Korean men and women. JAMA, 293: 194–202, 2005.
19.
JopeRS and JohnsonGV. The glamour and gloom of glycogen synthase kinase-3. Trends Biochem Sci, 29: 95–102, 2004.
20.
KabatGC, KimMY, StricklerHD, ShikanyJM, LaneD, LuoJ, NingY, GunterMJ, and RohanTE. A longitudinal study of serum insulin and glucose levels in relation to colorectal cancer risk among postmenopausal women. Br J Cancer, 106: 227–232, 2012.
21.
KanagasabaiR, KrishnamurthyK, DruhanLJ, and IlangovanG. Forced expression of heat shock protein 27 (Hsp27) reverses P-glycoprotein (ABCB1)-mediated drug efflux and MDR1 gene expression in Adriamycin-resistant human breast cancer cells. J Biol Chem, 286: 33289–33300, 2011.
22.
KoroljowS. Two cases of malignant tumors with metastases apparently treated successfully with hypoglycemic coma. Psychiatr Q, 36: 261–270, 1962.
23.
LarssonSC, MantzorosCS, and WolkA. Diabetes mellitus and risk of breast cancer: a meta-analysis. Int J Cancer, 121: 856–862, 2007.
24.
LawlorDA, SmithGD, and EbrahimS. Hyperinsulinaemia and increased risk of breast cancer: findings from the British Women's Heart and Health Study. Cancer Causes Contr, 15: 267–275, 2004.
25.
LiaoS, LiJ, WeiW, WangL, ZhangY, LiJ, WangC, and SunS. Association between diabetes mellitus and breast cancer risk: a meta-analysis of the literature. Asian Pac J Cancer Prev, 12: 1061–1065, 2011.
26.
LipscombeLL, GoodwinPJ, ZinmanB, McLaughlinJR, and HuxJE. The impact of diabetes on survival following breast cancer. Breast Cancer Res Treat, 109: 389–395, 2008.
27.
LoweJM, ChaH, YangQ, and FornaceAJJr., Nuclear factor-kappaB (NF-kappaB) is a novel positive transcriptional regulator of the oncogenic Wip1 phosphatase. J Biol Chem, 285: 5249–5257, 2010.
28.
LuX, NannengaB, and DonehowerLA. PPM1D dephosphorylates Chk1 and p53 and abrogates cell cycle checkpoints. Genes Dev, 19: 1162–1174, 2005.
29.
LuX, NguyenTA, MoonSH, DarlingtonY, SommerM, and DonehowerLA. The type 2C phosphatase Wip1: an oncogenic regulator of tumor suppressor and DNA damage response pathways. Cancer Metastasis Rev, 27: 123–135, 2008.
30.
LyngMB, LaenkholmAV, PallisgaardN, and DitzelHJ. Identification of genes for normalization of real-time RT-PCR data in breast carcinomas. BMC Cancer, 8: 20, 2008.
31.
ManjerJ, KaaksR, RiboliE, and BerglundG. Risk of breast cancer in relation to anthropometry, blood pressure, blood lipids and glucose metabolism: a prospective study within the Malmo Preventive Project. Eur J Cancer Prev, 10: 33–42, 2001.
32.
Marti-RenomMA, StuartAC, FiserA, SanchezR, MeloF, and SaliA. Comparative protein structure modeling of genes and genomes. Annu Rev Biophys Biomol Struct, 29: 291–325, 2000.
33.
MoorheadGB, Trinkle-MulcahyL, and Ulke-LemeeA. Emerging roles of nuclear protein phosphatases. Nat Rev Mol Cell Biol, 8: 234–244, 2007.
34.
MutiP, QuattrinT, GrantBJ, KroghV, MicheliA, SchunemannHJ, RamM, FreudenheimJL, SieriS, TrevisanM, and BerrinoF. Fasting glucose is a risk factor for breast cancer: a prospective study. Cancer Epidemiol Biomark Prev, 11: 1361–1368, 2002.
35.
Oliva-TrastoyM, BerthonaudV, ChevalierA, DucrotC, Marsolier-KergoatMC, MannC, and LeteurtreF. The Wip1 phosphatase (PPM1D) antagonizes activation of the Chk2 tumour suppressor kinase. Oncogene, 26: 1449–1458, 2007.
36.
OsakiY, TaniguchiS, TaharaA, OkamotoM, and KishimotoT. Metabolic syndrome and incidence of liver and breast cancers in Japan. Cancer Epidemiol, 36: 141–147, 2012.
37.
ParaviciniTM and TouyzRM. Redox signaling in hypertension. Cardiovasc Res, 71: 247–258, 2006.
38.
PeairsKS, BaroneBB, SnyderCF, YehHC, SteinKB, DerrRL, BrancatiFL, and WolffAC. Diabetes mellitus and breast cancer outcomes: a systematic review and meta-analysis. J Clin Oncol, 29: 40–46, 2011.
39.
RahmanAA, MakpolS, JamalR, HarunR, MokhtarN, and NgahWZ. Tocotrienol-rich fraction, [6]-gingerol and epigallocatechin gallate inhibit proliferation and induce apoptosis of glioma cancer cells. Molecules, 19: 14528–14541, 2014.
40.
RaoR, ZhangMZ, ZhaoM, CaiH, HarrisRC, BreyerMD, and HaoCM. Lithium treatment inhibits renal GSK-3 activity and promotes cyclooxygenase 2-dependent polyuria. Am J Physiol Ren Physiol, 288: F642–F649, 2005.
41.
RappK, SchroederJ, KlenkJ, UlmerH, ConcinH, DiemG, OberaignerW, and WeilandSK. Fasting blood glucose and cancer risk in a cohort of more than 140,000 adults in Austria. Diabetologia, 49: 945–952, 2006.
42.
RautaJ, AlarmoEL, KauraniemiP, KarhuR, KuukasjarviT, and KallioniemiA. The serine-threonine protein phosphatase PPM1D is frequently activated through amplification in aggressive primary breast tumours. Breast Cancer Res Treat, 95: 257–263, 2006.
43.
RayterS, ElliottR, TraversJ, RowlandsMG, RichardsonTB, BoxallK, JonesK, LinardopoulosS, WorkmanP, AherneW, LordCJ, and AshworthA. A chemical inhibitor of PPM1D that selectively kills cells overexpressing PPM1D. Oncogene, 27: 1036–1044, 2008.
44.
RogallaT, EhrnspergerM, PrevilleX, KotlyarovA, LutschG, DucasseC, PaulC, WieskeM, ArrigoAP, BuchnerJ, and GaestelM. Regulation of Hsp27 oligomerization, chaperone function, and protective activity against oxidative stress/tumor necrosis factor alpha by phosphorylation. J Biol Chem, 274: 18947–18956, 1999.
45.
SakaguchiK, HerreraJE, SaitoS, MikiT, BustinM, VassilevA, AndersonCW, and AppellaE. DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes Dev, 12: 2831–2841, 1998.
46.
SalimT, Sand-DejmekJ, and SjolanderA. The inflammatory mediator leukotriene D induces subcellular beta-catenin translocation and migration of colon cancer cells. Exp Cell Res, 321: 255–266, 2013.
47.
SamaanN, ZhongQ, FernandezJ, ChenG, HussainAM, ZhengS, WangG, and ChenQH. Design, synthesis, and evaluation of novel heteroaromatic analogs of curcumin as anti-cancer agents. Eur J Med Chem, 75: 123–131, 2014.
48.
ScataKA and El-DeiryWS. p53, BRCA1 and breast Cancer chemoresistance. Adv Exp Med Biol, 608: 70–86, 2007.
49.
SeyfriedTN, SandersonTM, El-AbbadiMM, McGowanR, and MukherjeeP. Role of glucose and ketone bodies in the metabolic control of experimental brain cancer. Br J Cancer, 89: 1375–1382, 2003.
50.
TakekawaM, AdachiM, NakahataA, NakayamaI, ItohF, TsukudaH, TayaY, and ImaiK. p53-inducible wip1 phosphatase mediates a negative feedback regulation of p38 MAPK-p53 signaling in response to UV radiation. EMBO J, 19: 6517–6526, 2000.
51.
Vona-DavisL, Howard-McNattM, and RoseDP. Adiposity, type 2 diabetes and the metabolic syndrome in breast cancer. Obes Rev, 8: 395–408, 2007.
52.
WuY, SarkissyanM, McGheeE, LeeS, and VadgamaJV. Combined inhibition of glycolysis and AMPK induces synergistic breast cancer cell killing. Breast Cancer Res Treat, 151: 529–539, 2015.
53.
WuY, YuX, YiX, WuK, DwabeS, AtefiM, ElshimaliY, KempKT2nd, BhatK, HaroJ, SarkissyanM, and VadgamaJV. Aberrant Phosphorylation of SMAD4 Thr277-Mediated USP9x-SMAD4 Interaction by Free Fatty Acids Promotes Breast Cancer Metastasis. Cancer Res, 77: 1383–1394, 2017.
XueF and MichelsKB. Diabetes, metabolic syndrome, and breast cancer: a review of the current evidence. Am J Clin Nutr, 86: s823–s835, 2007.
56.
ZengL, BiernackaKM, HollyJM, JarrettC, MorrisonAA, MorganA, WintersZE, FoulstoneEJ, ShieldJP, and PerksCM. Hyperglycaemia confers resistance to chemotherapy on breast cancer cells: the role of fatty acid synthase. Endocr Relat Cancer, 17: 539–551, 2010.
57.
ZhangN, WeiP, GongA, ChiuWT, LeeHT, ColmanH, HuangH, XueJ, LiuM, WangY, SawayaR, XieK, YungWK, MedemaRH, HeX, and HuangS. FoxM1 promotes beta-catenin nuclear localization and controls Wnt target-gene expression and glioma tumorigenesis. Cancer Cell, 20: 427–442, 2011.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
